Contact
searchSearch
HMP Global
Login

PROSTATE CANCER

Conference Coverage
Real-world PSA Progression After Enzalutamide or Abiraterone for Metastatic CRPC
06/24/2021
A real-world study presented at the virtual 2021 ASCO Annual Meeting evaluated prostate-specific antigen pattern progression and its association with OS among patients with metastatic CRPC who were treated with enzalutamide or abiraterone.
A real-world study presented at the virtual 2021 ASCO Annual Meeting evaluated prostate-specific antigen pattern progression and its association with OS among patients with metastatic CRPC who were treated with enzalutamide or abiraterone.
A real-world study presented at...
06/24/2021
Journal of Clinical Pathways
Conference Coverage
Physician- and Patient-Reported Outcomes Among Five Radiotherapy Methods for Prostate Cancer
06/21/2021
A recent study comparing radiotherapy methods for prostate cancer suggests that physician-reported toxicities may be lower for patients treated with high-dose-rate brachytherapy, and patient-reported outcomes may be worse for those treated...
A recent study comparing radiotherapy methods for prostate cancer suggests that physician-reported toxicities may be lower for patients treated with high-dose-rate brachytherapy, and patient-reported outcomes may be worse for those treated...
A recent study comparing...
06/21/2021
Journal of Clinical Pathways
Conference Coverage
Real-World Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer
06/14/2021
More than half of patients with metastatic castration-sensitive prostate cancer did not receive first-line treatment regimens associated with improved survival compared with ADT alone in the community practice setting.
More than half of patients with metastatic castration-sensitive prostate cancer did not receive first-line treatment regimens associated with improved survival compared with ADT alone in the community practice setting.
More than half of patients with...
06/14/2021
Journal of Clinical Pathways
Conference Coverage
Real-World Utilization of Advanced Therapies for Metastatic Castration-Sensitive Prostate Cancer
06/14/2021
In a large representative sample of US patients with metastatic castration-sensitive prostate cancer, less than one-third of patients received advanced therapies by 2018, and this was especially less frequent in Black patients.
In a large representative sample of US patients with metastatic castration-sensitive prostate cancer, less than one-third of patients received advanced therapies by 2018, and this was especially less frequent in Black patients.
In a large representative sample...
06/14/2021
Journal of Clinical Pathways
Conference Coverage
Real-World Utilization of Advanced Therapies for Metastatic Castration-Sensitive Prostate Cancer
06/14/2021
In a large representative sample of US patients with metastatic castration-sensitive prostate cancer, less than one-third of patients received advanced therapies by 2018, and this was especially less frequent in Black patients.
In a large representative sample of US patients with metastatic castration-sensitive prostate cancer, less than one-third of patients received advanced therapies by 2018, and this was especially less frequent in Black patients.
In a large representative sample...
06/14/2021
Journal of Clinical Pathways

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use